IBRX:NASDAQ, ImmunityBio, Inc.
IBRX stock overview
ImmunityBio, Inc. (IBRX:NASDAQ) closed at $9.18 on October 16, 2026,
down 8.20% on the day.
The stock trades 26.1% below its 52-week high of $12.43
and 370.8% above its 52-week low of $1.95.
Over the past year, it gained 282.5%.
ImmunityBio, Inc. is part of the Health Care sector.
Key figures
- Price
- $9.18
- Day change
- -8.20%
- Volume
- 21,439,357
- Average volume
- 11,008,864
- Market cap
- 9B+
- 52-week range
- $1.95 – $12.43
- 50-day average
- $8.52
- 200-day average
- $7.56
Performance
| 5D |
1M |
3M |
6M |
1Y |
| -9.29% |
+8.51% |
+22.48% |
+11.95% |
+282.50% |
Price action over the past year
In 252 trading sessions since October 16, 2025, IBRX closed higher on 125 days (50%).
Its best day was February 18, 2026 (+41.86%) and its worst was March 24, 2026 (-21.12%).
The stock moved 10% or more in a single session 19 times.
It opened at least 5% above the previous day's high 5 times.
Recent signals
IBRX news
-
Oct 16, 2026:
ImmunityBio Reports Phase 3 Data Showing 84% Cystectomy Avoidance at Three Years and Complete Responses Beyond 53 Months with ANKTIVA Plus BCG in BCG-Unresponsive NMIBC With CIS, With or Without Papillary Tumors
-
Oct 16, 2026:
ImmunityBio Reports Phase 3 Data Showing 84% Cystectomy Avoidance at Three Years and Complete Responses Beyond 53 Months with ANKTIVA® Plus BCG in BCG-Unresponsive NMIBC With CIS, With or Without Papillary Tumors
-
Oct 15, 2026:
FDA Expands ImmunityBio's Anktiva Label in Bladder Cancer
-
Oct 15, 2026:
IBRX Stock Eyes Weekly Slump Despite Anktiva FDA Win — Retail Stays Cautious Ahead Of Founder's Trial Talk
-
Oct 15, 2026:
IBRX Stock Eyes Weekly Slump Despite Anktiva FDA Win Retail Stays Cautious Ahead Of Founders Trial Talk
-
Oct 14, 2026:
FDA Expands ANKTIVA® Approval for BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer to Cover Both Papillary and CIS Disease
-
Oct 14, 2026:
FDA Expands ANKTIVA Approval for BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer to Cover Both Papillary and CIS Disease
-
Oct 14, 2026:
IBRX Stock Rallies After FDA Clears Broader Anktiva Use In Bladder Cancer Months Ahead Of Deadline
About ImmunityBio, Inc.
ImmunityBio Inc is a late-clinical-stage immunotherapy company developing next-generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate (natural killer cell and macrophage) and adaptive (T cell) immune systems to create long-term immunological memory.
Similar stocks
Find more stocks like IBRX with the
Spikes,
Gaps,
Breakouts and
Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.